
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol. , 25 April 2022
Sec. Ethnopharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.897243
This article is a correction to:
Bioassay-Guided Interpretation of Antimicrobial Compounds in Kumu, a TCM Preparation From Picrasma quassioides’ Stem via UHPLC-Orbitrap-Ion Trap Mass Spectrometry Combined With Fragmentation and Retention Time Calculation
by Hu, H., Hu, C., Peng, J., Ghosh, A. K., Khan, A., Sun, D. and Luyten, W. (2021). Front. Pharmacol. 12:761751. doi: 10.3389/fphar.2021.761751
In the original article, there was a mistake in Table 3 as published. The IC50, and MBC calculations of positive controls were unintentionally incorrect when generated by software Graphpad, and may make people confused about their high IC50 values in the original manuscript. Hence, the tests of these compounds were repeated twice again to confirm these results. The corrected Table 3 appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Picrasma quassioides, kumu, beta-carboline, orbitrap elite, MS fragmenter, fragmentation prediction
Citation: Hu H, Hu C, Peng J, Ghosh AK, Khan A, Sun D and Luyten W (2022) Corrigendum: Bioassay-Guided Interpretation of Antimicrobial Compounds in Kumu, a TCM Preparation From Picrasma quassioides’ Stem via UHPLC-Orbitrap-Ion Trap Mass Spectrometer Combined With Fragmentation and Retention Time Calculation. Front. Pharmacol. 13:897243. doi: 10.3389/fphar.2022.897243
Received: 15 March 2022; Accepted: 29 March 2022;
Published: 25 April 2022.
Edited and reviewed by:
Mukhlesur Rahman, University of East London, United KingdomCopyright © 2022 Hu, Hu, Peng, Ghosh, Khan, Sun and Luyten. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Haibo Hu, aGFpYm8uaHVAa3VsZXV2ZW4uYmU=; Walter Luyten, d2FsdGVyLmx1eXRlbkBrdWxldXZlbi5iZQ==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.